Exploring a better way to patient care
Autoimmune diseases can involve virtually any cell or organ system, and have a global prevalence around 345,000,000 today. Compare that to the global prevalence of cancer at 12,740,000, and you start to see the vast impact these diseases have.
With such an enormous need, we’re focused on the discovery of new biomarkers and systems that enables more accurate and early diagnosis. Through novel biomarkers like HMGCR, PS/PT and CCP3 we provide clinicians with the tools to make more accurate diagnoses, earlier in the disease process — so that people suffering from autoimmune diseases can begin treatment as soon possible to positively impact the course of the disease.
Addressing a multitude of autoimmune diseases.
We’ve worked with laboratorians, clinicians, and research partners around the world to create products that accurately test autoimmune disorders. This deeper knowledge has enabled us to improve the quality of testing for the following autoimmune diseases:
Inflammatory Bowel Disease (IBD)
IBD is a group of chronic inflammatory diseases, including Crohn’s disease and ulcerative colitis that affect the colon and small intestine.
Autoimmune Liver Disease
In this chronic disease, the body’s immune system attacks the cells of the liver, causing inflammation and damage.
Rheumatoid Arthritis (RA)
This chronic disease causes pain, swelling, stiffness, and loss of function in the joints.
Vasculitis refers to a group of rare diseases involving inflammation of blood vessels.
Antiphospholipid Syndrome (APS)
This disorder manifests clinically as venous or arterial thrombosis and/or fetal loss.
Connective Tissue Disease (CTD)
CTD refers to several autoimmune disorders such as lupus, systemic sclerosis, mixed connective tissue disease, and Sjӧgren’s disease.
This relative common disease is caused by an immune response to gluten, and leads to damages of the small intestine and other longterm health problems.